ABBVRGX-314 is under clinical development by AbbVie and currently in Phase II for Diabetic Retinopathy. According to GlobalData, Phase II drugs for Diabetic Retinopathy have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABBVRGX-314’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RGX-314 is under development for the treatment of wet age-related macular degeneration, diabetic retinopathy and anti-VEGF treated retinal diseases. It is administered through subretinal and suprachoroidal route. It targets vascular endothelial growth factor A (VEGF-A). The therapeutic candidate is a gene therapy (adeno-associated virus vector serotype 8 (AAV8) vector encoding a gene for monoclonal antibody fragment which binds to VEGF) based on the NAV technology platform.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of ABBVRGX-314’s drug-specific PTSR and LoA scores, buy the report here.